Abstract Purpose of the Review Esophageal cancer is the sixth most common cause of
cancer death globally. Squamous cell carcinoma of the esophagus (ESCC) is the …

Simple Summary Over 500,000 individuals died due to esophageal cancer (EC) worldwide
in 2020. More than four decades of etiological research have predominantly focused on the …

The incidence of oesophageal cancer, in particular adenocarcinoma, has markedly
increased over the last four decades with adenocarcinoma becoming the dominant subtype …

Background & Aims Biomarkers are needed to risk stratify after chemoradiotherapy for
localized esophageal cancer. These could improve identification of patients at risk for cancer …

Esophageal squamous cell carcinoma (ESCC) is among the most deadly forms of human
malignancy characterized by late stage diagnosis, metastasis, therapy resistance and …

Esophageal cancer is still one of the most common cancers in the world. We review the
appropriate treatments at different stages of esophageal cancer and also analyze the …

The primary objective of these guidelines was to provide general clinicians with information
that would guide them to make informed choices from the available diagnosis/treatment …

Abstract Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits
antitumor effects alone or in combination with other drugs in various cancers. However, its …

Esophageal cancer is the 6th leading cause of cancer-related mortality worldwide with a
fiveyear overall survival of less than 25%. 1, 2 Patients rarely present at an early stage as …

Outcomes for patients with esophageal cancer have improved over the last decade with the
implementation of multimodality therapy. There are currently no comprehensive guidelines …